Clinician Reference
Nicotinamide adenine dinucleotide: NAD+ versus NMN and NR
Three compounds get discussed as if they were interchangeable. They are not. This page sets out how nicotinamide adenine dinucleotide differs from its two common oral precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — across conversion pathway, route, and regulatory status.
The short answer
NAD+ is the end product. NMN and NR are precursors that a cell must transport and convert before any NAD+ exists. Giving a precursor orally and giving the coenzyme parenterally are different interventions with different kinetics, and the published literature on one does not transfer cleanly to the other.
| NAD+ | NMN | NR | |
|---|---|---|---|
| Full name | Nicotinamide adenine dinucleotide | Nicotinamide mononucleotide | Nicotinamide riboside |
| Position in pathway | End product / active coenzyme | One step upstream | Two steps upstream |
| Conversion required | None — already the active form | NMNAT converts NMN to NAD+ | NRK phosphorylates NR to NMN, then NMNAT to NAD+ |
| Typical route | Subcutaneous injection or IV infusion | Oral | Oral |
| First-pass metabolism | Bypassed | Subject to it | Subject to it |
| Molecular weight | 663.43 g/mol | 334.22 g/mol | 255.25 g/mol |
| CAS number | 53-84-9 | 1094-61-7 | 1341-23-7 |
| Common US classification | Not FDA-approved as a drug; supplied to licensed practitioners | Contested — see regulatory note below | Marketed as a dietary ingredient, subject of NDI notifications |
Why the conversion step matters
The salvage pathway is not a passive funnel. Each step has a transporter and an enzyme with finite capacity, and both vary by tissue and by individual. NR must first be phosphorylated by nicotinamide riboside kinase; NMN must reach the interior of the cell before NMNAT can act on it. A precursor dose therefore does not map linearly onto a rise in tissue NAD+, and where that rise occurs depends on which tissues express the relevant machinery.
Delivering the intact coenzyme parenterally removes the conversion question but introduces its own: NAD+ is a large, charged molecule, and how much of an administered dose reaches the intracellular compartment as intact NAD+ — rather than being degraded extracellularly to nicotinamide and re-entering the salvage pathway anyway — is an open and actively debated question in the literature. Practitioners should be aware that this is contested rather than settled.
Regulatory status is the sharpest difference
This is where the three compounds diverge most, and it is the part most often glossed over.
NR has been the subject of new dietary ingredient notifications and is broadly marketed as a dietary ingredient in the United States.
NMN occupies contested ground. Its status as a permissible dietary supplement ingredient has been the subject of ongoing FDA position changes and industry dispute, and the situation has shifted more than once. Anyone relying on its classification should confirm the current position directly rather than trusting secondary summaries, including this one.
NAD+ in injectable form is not an FDA-approved drug product. It is supplied to licensed physicians, clinics and healthcare practices for use within the scope of their license and applicable state and federal law. It is not a consumer product and Mitova Bioscience does not sell it to the general public.
A practical consequence: because the three sit in different regulatory categories, a claim, a marketing channel, or a purchasing route that is appropriate for one may be inappropriate for another. Treat them as three separate compliance questions, not one.
What this means when sourcing
If your protocol calls for the injectable coenzyme, you are buying NAD+ — CAS 53-84-9, lyophilized, reconstituted at the point of use, with a lot-matched certificate of analysis confirming identity and purity. Precursor material is a different product with a different specification and a different supply chain, and purity verification on one says nothing about the other.
For the biochemistry of the coenzyme itself — the redox couple, the consuming enzyme families, and the salvage pathway — see What is NAD+.
Regulatory notice
NAD+ is not an FDA-approved drug product. Nothing on this page is medical, legal or regulatory advice, and nothing here should be read as a claim that NAD+, NMN or NR diagnoses, treats, cures or prevents any disease. Regulatory classifications change; confirm the current status of any compound directly with the relevant authority. Mitova Bioscience supplies licensed practitioners only.
Common questions
Is NMN the same as NAD+?
No. NMN is nicotinamide mononucleotide, a precursor one enzymatic step upstream of NAD+. It must be converted by NMNAT before any NAD+ results. They differ in molecular weight, CAS number, route of administration and regulatory classification.
Why not just give the precursor orally instead of injecting NAD+?
That is a legitimate clinical question and the answer is not settled. Oral precursors avoid injection entirely but depend on transport and conversion capacity that varies by tissue and individual. Parenteral NAD+ bypasses first-pass metabolism but raises its own questions about how much reaches the intracellular compartment intact. The determination belongs to the treating practitioner reading the primary literature.
Does a purity certificate for NMN apply to NAD+?
No. They are different compounds with different CAS numbers and different analytical methods. A certificate of analysis is lot-specific and compound-specific. Always match the COA to the exact material and lot you received.
Which form does Mitova Bioscience supply?
NAD+ — the intact coenzyme, CAS 53-84-9 — as lyophilized powder in 500 mg and 1000 mg vials, verified at ≥99% purity by HPLC with a lot-matched certificate of analysis. Supplied to licensed practitioners only.